NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT06406465 2026-03-18
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07129252 2026-03-10
BRAVESST2
Crinetics Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT07458906 2026-03-09
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The First Affiliated Hospital of Xiamen University
Phase NA Recruiting
NCT07377487 2026-02-20
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT06941480 2026-02-19
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Memorial Sloan Kettering Cancer Center
Phase 1 Not yet recruiting
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT07080242 2026-02-09
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
Phase 1 Recruiting
NCT07174583 2026-01-23
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT07337447 2026-01-13
REWENEC 01
Hospices Civils de Lyon
Phase 2 Not yet recruiting
NCT07278479 2026-01-09
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Phase 1/2 Recruiting
NCT05978284 2026-01-05
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07038096 2026-01-05
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT05470595 2025-12-30
LCNEC-ALPINE
Technische Universität Dresden
Phase 2 Active not recruiting
NCT02595424 2025-12-29
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting